QuantumCyte, founded with a mission to revolutionize cancer drug assays, focuses on developing advanced technology for isolating complex regions of interest (ROIs) from FFPE tissue slides. Their core product, an automated tissue dissection system, utilizes digital tissue maps to precisely isolate ROIs containing informative biomarkers. This innovation aims to enhance the accuracy and efficiency of cancer research and drug development, targeting the oncology market and research institutions.
Notable figures associated with QuantumCyte include experts in oncology and biomedical engineering, though specific names are not provided. The company has achieved significant milestones, such as the development and implementation of their QCPRECISE! Platform, which has been featured in various scientific posters and publications. QuantumCyte's impact is evident in its contribution to more precise and informative cancer drug assays, potentially accelerating the discovery of effective cancer treatments.
